{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:48:10Z","timestamp":1779886090640,"version":"3.53.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T00:00:00Z","timestamp":1601942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>In this pooled, post hoc analysis of a phase 2 trial and the phase 3 TEMSO, TOWER, and TENERE clinical trials, long-term efficacy and safety of teriflunomide were assessed in subgroups of patients with relapsing multiple sclerosis (MS) defined by prior treatment status.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Patients were classified according to their prior treatment status in the core and core plus extension periods. In the core period, patients were grouped according to treatment status at the start of the study: treatment naive (no prior disease-modifying therapy [DMT] or DMT &gt;\u20092\u2009years prior to randomization), previously treated with another DMT (DMT &gt;\u20096 to \u226424\u2009months prior to randomization), and recently treated with another DMT (DMT \u22646\u2009months prior to randomization). In the core plus extension period, patients were re-baselined to the time of starting teriflunomide 14\u2009mg and grouped according to prior treatment status at that time point. Efficacy endpoints included annualized relapse rate (ARR), probability of confirmed disability worsening (CDW) over 12\u2009weeks, and Expanded Disability Status Scale (EDSS) score. The incidence of adverse events was also assessed.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Most frequently received prior DMTs at baseline were glatiramer acetate and interferon beta-1a across treatment groups. Teriflunomide 14\u2009mg significantly reduced ARR versus placebo in the core period, regardless of prior treatment status. In the core and extension periods, adjusted ARRs were low (0.193\u20130.284) in patients treated with teriflunomide 14\u2009mg across all subgroups. Probability of CDW by Year 4 was similar across subgroups; by Year 5, the percentage of patients with 12-week CDW was similar in treatment-naive patients and patients recently treated with another DMT (33.9 and 33.7%, respectively). EDSS scores were stable over time in all prior-treatment subgroups. There were no new or unexpected safety signals. Limitations include selective bias due to patient attrition, variability in subgroup size, and lack of magnetic resonance imaging outcomes.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The efficacy and safety of teriflunomide 14\u2009mg was similar in all patients with relapsing MS, regardless of prior treatment history.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>Phase 2 trial core: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01487096\">NCT01487096<\/jats:ext-link>; Phase 2 trial extension: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00228163\">NCT00228163<\/jats:ext-link>; TEMSO core: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00134563\">NCT00134563<\/jats:ext-link>; TEMSO extension: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00803049\">NCT00803049<\/jats:ext-link>; TOWER: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00751881\">NCT00751881<\/jats:ext-link>; TENERE: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00883337\">NCT00883337<\/jats:ext-link>.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12883-020-01937-4","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T18:03:56Z","timestamp":1602007436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis"],"prefix":"10.1186","volume":"20","author":[{"given":"Giancarlo","family":"Comi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 E.","family":"Meca-Lallana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Vermersch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Parajeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houari","family":"Korideck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Chavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia K.","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,6]]},"reference":[{"key":"1937_CR1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.neurol.2018.03.012","volume":"174","author":"D Biotti","year":"2018","unstructured":"Biotti D, Ciron J. First-line therapy in relapsing remitting multiple sclerosis. Rev Neurol (Paris). 2018;174:419\u201328.","journal-title":"Rev Neurol (Paris)"},{"key":"1937_CR2","doi-asserted-by":"publisher","first-page":"k4674","DOI":"10.1136\/bmj.k4674","volume":"363","author":"F De Angelis","year":"2018","unstructured":"De Angelis F, John NA, Brownlee WJ. Disease-modifying therapies for multiple sclerosis. BMJ. 2018;363:k4674.","journal-title":"BMJ."},{"key":"1937_CR3","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","volume":"7","author":"DD Mikol","year":"2008","unstructured":"Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer acetate in relapsing MS disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7:903\u201314.","journal-title":"Lancet Neurol"},{"key":"1937_CR4","unstructured":"Genzyme Corporation. AUBAGIO\u00ae (teriflunomide) prescribing information. (2019) http:\/\/products.sanofi.us\/Aubagio\/Aubagio.pdf. Accessed 29 Oct 2019."},{"key":"1937_CR5","unstructured":"Sanofi-Aventis Groupe. AUBAGIO (teriflunomide) summary of product characteristics. (2020) https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aubagio-epar-product-information_en.pdf. Accessed 19 Aug 2020."},{"key":"1937_CR6","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1212\/01.wnl.0000203121.04509.31","volume":"66","author":"PW O'Connor","year":"2006","unstructured":"O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66:894\u2013900.","journal-title":"Neurology"},{"key":"1937_CR7","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","volume":"365","author":"P O'Connor","year":"2011","unstructured":"O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293\u2013303.","journal-title":"N Engl J Med"},{"key":"1937_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","volume":"13","author":"C Confavreux","year":"2014","unstructured":"Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:247\u201356.","journal-title":"Lancet Neurol"},{"key":"1937_CR9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/1352458513507821","volume":"20","author":"P Vermersch","year":"2014","unstructured":"Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler. 2014;20:705\u201316.","journal-title":"Mult Scler"},{"key":"1937_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1177\/1352458517695468","volume":"24","author":"MS Freedman","year":"2018","unstructured":"Freedman MS, Wolinsky JS, Comi G, Kappos L, Olsson TP, Miller AE, et al. The efficacy of teriflunomide in patients who received prior disease-modifying treatments: subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies. Mult Scler. 2018;24:535\u20139.","journal-title":"Mult Scler"},{"key":"1937_CR11","doi-asserted-by":"publisher","first-page":"eaao5563","DOI":"10.1126\/scitranslmed.aao5563","volume":"11","author":"L Klotz","year":"2019","unstructured":"Klotz L, Eschborn M, Lindner M, Liebmann M, Herold M, Janoschka C, et al. Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. Sci Transl Med. 2019;11:eaao5563.","journal-title":"Sci Transl Med"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01937-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-020-01937-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-020-01937-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T06:46:05Z","timestamp":1633502765000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-020-01937-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,6]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1937"],"URL":"https:\/\/doi.org\/10.1186\/s12883-020-01937-4","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,6]]},"assertion":[{"value":"8 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the multiple studies comprising this post hoc pooled analysis, the protocols were approved by central and local ethics committees and the review board at each of the multiple sites (see Supplementary Table\u00a0 in supplementary information for details). Patients provided written informed consent before participating in the trials. All studies were carried out in accordance with the International Conference on Harmonisation Guidelines for Good Clinical Practice and the World Medical Association\u2019s Declaration of Helsinki and its amendments.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"<b>Giancarlo Comi:<\/b> Compensation for consulting services and\/or speaking activities (Almirall, Biogen, Celgene, Excemed, Forward Pharma, Genzyme, Merck, Novartis, Receptos, Roche, Sanofi, Teva); fees for non-CME services (Almirall, Bayer, Biogen, Excemed, Genzyme, Merck Serono, Novartis, Receptos, Sanofi, SSIF, Teva). <b>Mark S Freedman:<\/b> Research\/educational grant support (Genzyme); honoraria\/consulting fees (Actelion [J&J], Bayer HealthCare, Biogen, Chugai, EMD Canada, Genzyme, Merck, Novartis, Roche, Sanofi, Teva Canada Innovation); member of company advisory boards\/board of directors\/other similar group (Bayer HealthCare, Biogen, Chugai, Genzyme, Merck Serono, Novartis, Roche, Sanofi, Teva Canada Innovation). <b>Jos\u00e9 E Meca-Lallana:<\/b> Grants or speaking and consultation honoraria (Almirall, Biogen, Celgene, Genzyme, Merck, Novartis, Roche, Teva). <b>Patrick Vermersch:<\/b> Honoraria, consulting fees (Almirall, Bayer, Biogen, Celgene, Genzyme, GSK, Merck Serono, Novartis, Sanofi, Servier, Teva); research support (Bayer, Biogen, Genzyme, Merck Serono, Sanofi). <b>Byoung Joon Kim:<\/b> Honoraria, consulting fees (Astellas, Bayer, Celltrion, Corestem, Genuv, Genzyme). <b>Alexander Parajeles:<\/b> Nothing to disclose. <b>Keith R Edwards:<\/b> Consulting fees (EMD Serono); research support (Biogen, Genentech, Novartis, Sanofi). <b>Ralf Gold:<\/b> Consulting fees (Bayer Schering, Biogen, Elan, Genzyme, Roche, Teva); grant\/research support (Bayer Schering, Biogen, Genzyme, Teva). <b>Houari Korideck and Elizabeth M Poole:<\/b> Employees of Sanofi at the time the study was conducted. <b>Jeffrey Chavin:<\/b> Employee of Sanofi. <b>Patricia K Coyle:<\/b> Consulting fees (Accordant, Biogen, Genentech\/Roche, Genzyme\/Sanofi, Novartis, Serono, TG Therapeutics); research support (Actelion, Alkermes, Corrona LLD, Genentech\/Roche, MedDay, NINDS, Novartis).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"364"}}